Life Science Investing CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
Life Science Investing CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer Annual Meeting
Life Science Investing CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025
CORRECTION: Nextech3D.ai Provides Shareholder Update on Krafty Labs Acquisition and Announces $321,917 CEO Investment
Goldgroup Secures Ownership of the San Francisco Gold Mine Acquiring 100% of Molimentales del Noroeste, S.A. De C.V.
